Qure.ai is a global AI health innovator whose software analyses chest X-rays, CT scans, point-of-care ultrasounds, and other medical images to flag conditions such as tuberculosis, pneumonia, lung cancer, stroke, and other neuro-critical findings. The company’s platforms are deployed in more than 4,800 sites across 105+ countries, helping clinicians and health workers shorten TB diagnosis times from roughly two weeks to just one to two days, even in remote regions with limited clinical staff. Its technology is already used on Mount Everest, in sub-Saharan Africa, and rural Southeast Asia to bring diagnostics to hard-to-reach populations. Qure.ai’s product suite supports early disease detection, triage, and care-pathway management for both public-health programs and commercial healthcare providers. The firm also collaborates with pharmaceutical and medical-device companies to accelerate research and treatment developments. Looking ahead, Qure.ai plans to build an open-source, multi-modal database and new AI algorithms for point-of-care ultrasound, further expanding its lung-health capabilities. Although the article does not disclose current revenue figures, the multimillion-dollar Gates Foundation grant underscores external confidence in Qure.ai’s impact and future growth trajectory.

Total raised

$125M

Funding rounds

6

Latest round

Series D

Latest activity

Sep 2024